Researchers identify therapy that shrinks tumors in patients with multiple myeloma

March 8, 2017, Mayo Clinic
Credit: Mayo Clinic

Mayo Clinic researchers have found that an experimental drug, LCL161, stimulates the immune system, leading to tumor shrinkage in patients affected by multiple myeloma. The findings are published in Nature Medicine.

Multiple myeloma is a blood cancer that affects - that normally produce antibodies to fight infection. Rather than produce helpful antibodies, the cancer cells, as they grow, secrete large amounts of a single antibody that accumulate in the body, causing kidney problems and infections.

"The drug, LCL161, was initially developed to promote tumor death," says Marta Chesi, Ph.D., a Mayo Clinic biochemist and lead author of the study of 25 Multiple Myeloma patients. "However, we found that the drug does not kill directly. Rather, it makes them more visible to the immune system that recognizes them as foreigner invaders and eliminates them."

Mayo Clinic researchers will conduct a follow-up clinical trial of LCL161 in combination with an inhibitor of immune checkpoints that has been widely used in many cancer treatments to evaluate if LCL161 could represent a potential new treatment option.

"The model for preclinical studies to predict with great accuracy which drugs would work in the clinic was developed a decade ago," says Dr. Chesi. "And it has been instrumental in the prioritization of which experimental therapeutics should be tested in patients with multiple myeloma."

The research highlights the importance of studying the effects of drugs not only on the tumor cells in a culture plate, but also on the interaction of the tumor cells with their own microenvironment. The finding that LCL161 is active against suggests that similar drugs may have broader clinical activity than previously thought.

Explore further: New treatments to extend life for multiple myeloma patients

More information: Marta Chesi et al. IAP antagonists induce anti-tumor immunity in multiple myeloma, Nature Medicine (2016). DOI: 10.1038/nm.4229

Related Stories

New treatments to extend life for multiple myeloma patients

February 10, 2017
Multiple myeloma is a cancer of the plasma cells that reside inside bone marrow. Plasma cells produce certain proteins that build up the immune system. In abnormal quantities, these proteins damage the body and compromise ...

Study shows that choice of medical center impacts life expectancy of multiple myeloma patients

October 26, 2016
People diagnosed with multiple myeloma are more likely to live longer if they are treated at a medical center that sees many patients with this blood cancer. Mayo Clinic researchers published these findings today in the Journal ...

Preclinical tests may lead to new approach to treat CNS lymphoma

August 12, 2013
A drug recently approved for use in multiple myeloma is now being tested for its ability to fight central nervous system (CNS) lymphoma, a deadly cancer of the immune system that can affect the brain, spinal cord and fluid, ...

Empliciti approved for multiple myeloma

November 30, 2015
(HealthDay)—Empliciti (elotuzumab), in combination with two other drugs, has been approved by the U.S. Food and Drug Administration to treat the blood cancer multiple myeloma. The drug is only approved for patients who ...

Researchers discover underlying cause of myeloma

February 11, 2016
Yale Cancer Center researchers have identified what causes a third of all myelomas, a type of cancer affecting plasma cells. The findings, published Feb. 10 in the New England Journal of Medicine, could fundamentally change ...

New model for understanding myeloma

October 12, 2016
All cancers originate from an earlier, or precursor, state—such as a benign or asymptomatic condition. To develop new approaches to cancer prevention, scientists have attempted to grow tumor cells from  precursor states ...

Recommended for you

More than 2,500 cancer cases a week could be avoided

March 23, 2018
More than 135,500 cases of cancer a year in the UK could be prevented through lifestyle changes, according to new figures from a Cancer Research UK landmark study published today.

Metastatic lymph nodes can be the source of distant metastases in mouse models of cancer

March 22, 2018
A study by Massachusetts General Hospital (MGH) investigators finds that, in mouse models, cancer cells from metastatic lymph nodes can escape into the circulation by invading nodal blood vessels, leading to the development ...

Researchers examine role of fluid flow in ovarian cancer progression

March 22, 2018
New research from Virginia Tech is moving physicians closer to pinpointing a predictor of ovarian cancer, which could lead to earlier diagnosis of what is know as the "silent killer."

Could a pap test spot more than just cervical cancer?

March 22, 2018
Pap tests have helped drive down rates of cervical cancer, and a new study suggests they also could be used to detect other gynecologic cancers early.

Researchers identify compound to prevent breast cancer cells from activating in brain

March 22, 2018
Researchers at Houston Methodist used computer modeling to find an existing investigational drug compound for leukemia patients to treat triple negative breast cancer once it spreads to the brain.

Probing RNA epigenetics and chromatin structures to predict drug resistance in leukemia

March 22, 2018
Drug resistance is a major obstacle to effective treatment for patients with cancer and leukemia. Epigenetic modifying drugs have been proven effective for some patients with hematologic malignancies, such as myelodysplastic ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.